Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial

被引：0
|
作者：
Le Heuzey, Jean-Yves [1 ]
Marijon, Eloi [1 ]
Connolly, Stuart [2 ]
Brueckmann, Martina [3 ]
Yang, Sean [2 ]
Pogue, Janice [2 ]
Eikelboom, John [2 ]
Ezekowitz, Michael [4 ]
Themeles, Ellison [2 ]
Wallentin, Lars [5 ]
Yusuf, Salim [2 ]
机构：
[1] Hop Europeen Georges Pompidou, Paris, France
[2] Populat Hlth Rsch Inst, Hamilton, ON, Canada
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Cardiovasc Rsch Fdn, Wynnewood, PA USA
[5] Uppsala Clin Rsch Cntr, Uppsala, Sweden
来源：
STROKE | 2013年 / 44卷 / 02期
关键词：
Sudden cardiac death; Heart failure; Embolism; Anticoagulation; Atrial fibrillation;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
    Paikin, Jeremy S.
    Haroun, Michelle J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 279 - 286
  • [2] Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
    Boehm, Michael
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Eikelboom, John W.
    Hohnloser, Stefan H.
    Reilly, Paul A.
    Schumacher, Helmut
    Brueckmann, Martina
    Schirmer, Stephan H.
    Kratz, Mario T.
    Yusuf, Salim
    Diener, Hans-Christoph
    Hijazi, Ziad
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (23) : 2481 - 2493
  • [3] Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
    Marin, Francisco
    Roldan, Vanessa
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1087 - 1090
  • [4] Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
    DiNicolantonio, James J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1101 - 1111
  • [5] Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran The RE-LY Trial
    Hart, Robert G.
    Diener, Hans-Christoph
    Yang, Sean
    Connolly, Stuart J.
    Wallentin, Lars
    Reilly, Paul A.
    Ezekowitz, Michael D.
    Yusuf, Salim
    STROKE, 2012, 43 (06) : 1511 - +
  • [6] Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial
    Ferreira, Jorge
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Brueckmann, Martina
    Fraessdorf, Mandy
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (09) : 1053 - 1061
  • [7] Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice
    Heidbuchel, Hein
    Verhamme, Peter
    ACTA CARDIOLOGICA, 2010, 65 (05) : 491 - 497
  • [8] Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
    Khoo, Chee W.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) : 685 - 687
  • [9] Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial
    Westenbrink, B. D.
    Alings, M.
    Connolly, S. J.
    Eikelboom, J.
    Ezekowitz, M. D.
    Oldgren, J.
    Yang, S.
    Pongue, J.
    Yusuf, S.
    Wallentin, L.
    van Gilst, W. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 699 - 707
  • [10] Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial
    Proietti, M.
    Hijazi, Z.
    Andersson, U.
    Connolly, S. J.
    Eikelboom, J. W.
    Ezekowitz, M. D.
    Lane, D. A.
    Oldgren, J.
    Roldan, V.
    Yusuf, S.
    Wallentin, L.
    JOURNAL OF INTERNAL MEDICINE, 2018, 283 (03) : 282 - 292
12345